Clinical characteristics of responders and nonresponders
| Characteristics . | Median levels . | P . | |
|---|---|---|---|
| NR (n = 35) . | R (n = 16) . | ||
| Age, y | 67 | 69 | .428 |
| MDS duration, d | 670 | 321 | .951 |
| BM biopsy cellularity, % | 70 | 55 | .152 |
| BM blasts, % | 3 | 2 | .0163-150 |
| PRBC duration, d | 91 | 132 | .79 |
| Platelet transfusion duration, d | 0 | 0 | .0133-150 |
| Maximum thalidomide dose, mg/d | 400 | 400 | .902 |
| Duration of maximum dose, d | 14 | 12 | .532 |
| Hemoglobin, g/dL | 8.9 | 8.7 | .59 |
| ANC, per μL | 1350 | 1050 | .136 |
| Platelets, per μL | 57 000 | 142 000 | .0033-150 |
| Initial IPSS scores | INT-1 | INT-1 | .468 |
| Characteristics . | Median levels . | P . | |
|---|---|---|---|
| NR (n = 35) . | R (n = 16) . | ||
| Age, y | 67 | 69 | .428 |
| MDS duration, d | 670 | 321 | .951 |
| BM biopsy cellularity, % | 70 | 55 | .152 |
| BM blasts, % | 3 | 2 | .0163-150 |
| PRBC duration, d | 91 | 132 | .79 |
| Platelet transfusion duration, d | 0 | 0 | .0133-150 |
| Maximum thalidomide dose, mg/d | 400 | 400 | .902 |
| Duration of maximum dose, d | 14 | 12 | .532 |
| Hemoglobin, g/dL | 8.9 | 8.7 | .59 |
| ANC, per μL | 1350 | 1050 | .136 |
| Platelets, per μL | 57 000 | 142 000 | .0033-150 |
| Initial IPSS scores | INT-1 | INT-1 | .468 |
NR indicates nonresponders; R, responders; for other abbreviations, see Tables 1 and 2.
Significant at .05 level.